Abstract
Plasma levels of the circulating metabolite of prostaglandin (PG) E2, 15-keto-13,14-dihydro-PGE2 (KH 2PGE 2), were determined radioimmunologically after conversion to the stable degradation product 11-deoxy-15-keto-13,14-dihydro-11, 16-cyclo-PGE2 (DKH2-cyclo-PGE 2). In healthy volunteers a plasma level of 25 + 2 pg/ml (mean ± S.E.M., n=24) was found. The plasma level of KH 2PGE 2 was significantly decreased after administration of acetylsalicylic acid (4 × 1 g/24 hours). A significant elevation of the plasma levels of the circulating metabolite of PGE 2 was observed in patients with bronchogenic carcinoma as compared to healthy controls, while no elevation was found in patients with chronic myeloid leukemia, lymphatic leukemia and non-Hodgkin lymphoma. The increased plasma levels of KH 2PGE 2 in the patients with bronchogenic carcinoma were independent of the clinical condition, histological type of tumor, tumor spread and therapeutic regimen. The results indicate that the elevated plasma level of the circulating PGE2 metabolite in patients with bronchogenic carcinoma is not an expression of malignant disease in general. On the other hand, the results do not suggest that the increase in the plasma level of KH 2 PGE 2 is a biochemical tumor marker closely related to a particular clinical feature of patients with bronchogenic carcinoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
